Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 Mar;61(3):654–660. doi: 10.1172/JCI108977

Androgen Receptor Content of the Normal and Hyperplastic Canine Prostate

Sydney A Shain 1, Robert W Boesel 1
PMCID: PMC372578  PMID: 76635

Abstract

A procedure was developed for measurement of androgen receptors in cytoplasmic extracts of prostates from intact dogs. The protocol utilized exchange saturation analysis at 15°C employing the synthetic androgen R1881 (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one) as the ligand probe and quantitatively detected total cytoplasmic androgen receptor (Rc, androgen-free receptor, and RcA, androgen-occupied receptor) present at the initiation of the assay. This protocol was employed in conjunction with a tissue mince saturation analysis procedure (for quantitation of nuclear androgen receptor) to quantitate total androgen receptor content of normal and hyperplastic prostates obtained from young (2.5- or 4.6-yr old) and aged (12.5-yr old) purebred dogs of known birth date.

The total cytoplasmic androgen receptor content (picomoles per prostate) of hyperplastic prostates was 4.6-fold greater than that of normal prostates. The total nuclear androgen receptor content of hyperplastic prostates (picomoles per prostate measured in crude nuclear preparations) was either 5.0- (4.6-yr-old dogs) or 7.8-fold (2.5-yr-old dogs) greater than that of normal prostates. However, androgen receptor content per cell was identical for hyperplastic and normal canine prostates, with the exception that nuclear androgen receptor was diminished in prostates from 2.5-yr-old dogs. The cell content per gram dry weight was identical for hyperplastic and normal canine prostates. We conclude that canine prostate hyperplasia is characterized by coordinate proliferation of androgen receptor-positive and androgen receptor-negative cells and is not a consequence of increased accumulation of 5α-dihydrotestosterone due to proliferation of androgen receptors per prostate cell.

Full text

PDF
654

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERG O. A. Parenchymatous hypertrophy of the canine prostate gland. Acta Endocrinol (Copenh) 1958 Feb;27(2):140–154. doi: 10.1530/acta.0.0270140. [DOI] [PubMed] [Google Scholar]
  2. Boesel R. W., Klipper R. W., Shain S. A. Identification of limited capacity androgen binding components in nuclear and cytoplasmic fractions of canine prostate. Endocr Res Commun. 1977;4(2):71–84. doi: 10.3109/07435807709073914. [DOI] [PubMed] [Google Scholar]
  3. Bonne C., Raynaud J. P. Assay of androgen binding sites by exchange with methyltrienolone (R 1881). Steroids. 1976 Apr;27(4):497–507. doi: 10.1016/0039-128x(76)90084-2. [DOI] [PubMed] [Google Scholar]
  4. Buller R. E., O'Malley B. W. The biology and mechanism of steroid hormone receptor interaction with the eukaryotic nucleus. Biochem Pharmacol. 1976 Jan;25(1):1–12. doi: 10.1016/0006-2952(76)90164-7. [DOI] [PubMed] [Google Scholar]
  5. Chamness G. C., McGuire W. L. Scatchard plots: common errors in correction and interpretation. Steroids. 1975 Oct;26(4):538–542. doi: 10.1016/0039-128x(75)90073-2. [DOI] [PubMed] [Google Scholar]
  6. GELLER J., BORA R., ROBERTS T., NEWMAN H., LIN A., SILVA R. TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION. JAMA. 1965 Jul 12;193:121–128. doi: 10.1001/jama.1965.03090020035009. [DOI] [PubMed] [Google Scholar]
  7. Gloyna R. E., Siiteri P. K., Wilson J. D. Dihydrotestosterone in prostatic hypertrophy. II. The formation and content of dihydrotestosterone in the hypertrophic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog. J Clin Invest. 1970 Sep;49(9):1746–1753. doi: 10.1172/JCI106392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gorski J., Gannon F. Current models of steroid hormone action: a critique. Annu Rev Physiol. 1976;38:425–450. doi: 10.1146/annurev.ph.38.030176.002233. [DOI] [PubMed] [Google Scholar]
  9. Jacobi G. H., Wilson J. D. The formation of 5alpha-androstane-3alpha, 17beta-diol by dog prostate. Endocrinology. 1976 Aug;99(2):602–610. doi: 10.1210/endo-99-2-602. [DOI] [PubMed] [Google Scholar]
  10. Shain S. A., Boesel R. W. Aging-associated diminished rat prostate androgen receptor content concurrent with decreased androgen dependence. Mech Ageing Dev. 1977 May-Jun;6(3):219–232. doi: 10.1016/0047-6374(77)90023-9. [DOI] [PubMed] [Google Scholar]
  11. Shain S. A., Boesel R. W., Axelrod L. R. Aging in the rat prostate. Reduction in detectable ventral prostate androgen receptor content. Arch Biochem Biophys. 1975 Mar;167(1):247–263. doi: 10.1016/0003-9861(75)90461-0. [DOI] [PubMed] [Google Scholar]
  12. Shain S. A., McCullough B., Nitchuk M., Boesel R. W. Prostate carcinogenesis in the AXC rat. Oncology. 1977;34(3):114–122. doi: 10.1159/000225203. [DOI] [PubMed] [Google Scholar]
  13. Shain S. A., McCullough B., Segaloff A. Spontaneous adenocarcinomas of the ventral prostate of aged A X C rats. J Natl Cancer Inst. 1975 Jul;55(1):177–180. doi: 10.1093/jnci/55.1.177. [DOI] [PubMed] [Google Scholar]
  14. Siiteri P. K., Wilson J. D. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970 Sep;49(9):1737–1745. doi: 10.1172/JCI106391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Walsh P. C., Wilson J. D. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest. 1976 Apr;57(4):1093–1097. doi: 10.1172/JCI108353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wendel E. F., Brannen G. E., Putong P. B., Grayhack J. T. The effect of orchiectomy and estrogens of benign prostatic hyperplasia. J Urol. 1972 Jul;108(1):116–119. doi: 10.1016/s0022-5347(17)60657-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES